← Back
Data updated: Mar 29, 2026
TORRENT PHARMS
NeurologyMetabolicCardiovascular
Generics
TORRENT PHARMS is a generic drug manufacturer focused on Neurology, Metabolic, Cardiovascular.
2001
Since
31
Drugs
-
Trials
574
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 50%
2 drugs
Metabolic 25%
1 drugs
Cardiovascular 25%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Active (11)
Discontinued (17)
AMLODIPINE BESYLATE OLANZAPINE CETIRIZINE HYDROCHLORIDE ALLERGY LOSARTAN POTASSIUM QUETIAPINE FUMARATE METFORMIN HYDROCHLORIDE RISPERIDONE ESCITALOPRAM OXALATE MONTELUKAST SODIUM CLOPIDOGREL BISULFATE PRAMIPEXOLE DIHYDROCHLORIDE ISOSORBIDE MONONITRATE DONEPEZIL HYDROCHLORIDE ZOLPIDEM TARTRATE FELODIPINE CITALOPRAM HYDROBROMIDE LEVOFLOXACIN
Company Info
- First Approval
- 2001-07-05
- Latest
- 2025-12-02
- Applications
- 39
FDA Sponsor Names
TORRENT PHARMSTORRENT PHARMS LTDTORRENT PHARMS LLC